EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
NASDAQ:XGN

Exagen - XGN Stock Forecast, Price & News

$2.89
-0.01 (-0.34%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.74
$2.93
50-Day Range
$2.10
$4.39
52-Week Range
$2.10
$12.40
Volume
105,855 shs
Average Volume
54,676 shs
Market Capitalization
$46.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60

Exagen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
232.2% Upside
$9.60 Price Target
Short Interest
Healthy
0.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.29
Upright™ Environmental Score
News Sentiment
0.96mentions of Exagen in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.79) to ($2.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.89 out of 5 stars

Medical Sector

51st out of 1,038 stocks

Medical Laboratories Industry

1st out of 25 stocks

XGN stock logo

About Exagen (NASDAQ:XGN) Stock

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

XGN Stock News Headlines

Exagen (NASDAQ:XGN) Given New $7.00 Price Target at Cowen
Exagen Inc. Reports Third Quarter 2022 Results
Exagen Announces Appointment of John Aballi as CEO
Exagen's Return On Capital Employed Overview
See More Headlines
Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

XGN Company Calendar

Last Earnings
11/10/2021
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/28/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XGN
Fax
N/A
Employees
219
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.60
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+232.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-26,850,000.00
Pretax Margin
-85.33%

Debt

Sales & Book Value

Annual Sales
$48.30 million
Book Value
$5.25 per share

Miscellaneous

Free Float
9,935,000
Market Cap
$46.99 million
Optionable
Not Optionable
Beta
1.17

Key Executives

  • Mr. Kamal Adawi M.S. (Age 43)
    MBA, CFO & Corp. Sec.
    Comp: $609.62k
  • Dr. Debra Jeske Zack (Age 65)
    Chief Medical Officer
    Comp: $626.62k
  • Mr. John Aballi (Age 37)
    CEO, Pres & Director
  • Mr. Mark Hazeltine (Age 48)
    Chief Operating Officer
  • Dr. Ming-Chou Lee Ph.D.
    Chief Technology Officer
  • Ryan Douglas
    Investors Relations Officer
  • Mr. John Wegener (Age 53)
    Sr. VP of Sales and Marketing
  • Dr. Andrew L. Concoff FACR
    M.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board













XGN Stock - Frequently Asked Questions

Should I buy or sell Exagen stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XGN shares.
View XGN analyst ratings
or view top-rated stocks.

What is Exagen's stock price forecast for 2023?

5 Wall Street research analysts have issued 1 year target prices for Exagen's stock. Their XGN share price forecasts range from $7.00 to $20.00. On average, they anticipate the company's stock price to reach $9.60 in the next year. This suggests a possible upside of 232.2% from the stock's current price.
View analysts price targets for XGN
or view top-rated stocks among Wall Street analysts.

How have XGN shares performed in 2022?

Exagen's stock was trading at $11.63 at the beginning of 2022. Since then, XGN stock has decreased by 75.2% and is now trading at $2.89.
View the best growth stocks for 2022 here
.

Are investors shorting Exagen?

Exagen saw a decrease in short interest in November. As of November 15th, there was short interest totaling 13,100 shares, a decrease of 34.8% from the October 31st total of 20,100 shares. Based on an average trading volume of 73,700 shares, the short-interest ratio is currently 0.2 days. Approximately 0.1% of the shares of the company are sold short.
View Exagen's Short Interest
.

When is Exagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our XGN earnings forecast
.

How were Exagen's earnings last quarter?

Exagen Inc. (NASDAQ:XGN) posted its earnings results on Wednesday, November, 10th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.04. The firm earned $12.25 million during the quarter, compared to analysts' expectations of $12.13 million. Exagen had a negative net margin of 82.81% and a negative trailing twelve-month return on equity of 55.31%. During the same quarter in the prior year, the business earned ($0.34) EPS.

What guidance has Exagen issued on next quarter's earnings?

Exagen updated its FY 2022 earnings guidance on Monday, November, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $40.00 million-$43.00 million, compared to the consensus revenue estimate of $38.10 million.

What is Ron Rocca's approval rating as Exagen's CEO?

5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees.

When did Exagen IPO?

(XGN) raised $50 million in an initial public offering on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO.

What is Exagen's stock symbol?

Exagen trades on the NASDAQ under the ticker symbol "XGN."

Who are Exagen's major shareholders?

Exagen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (7.78%), RTW Investments LP (6.45%), Platinum Investment Management Ltd. (2.16%), Perkins Capital Management Inc. (1.58%), Nantahala Capital Management LLC (0.93%) and UBS Group AG (0.84%). Insiders that own company stock include Hunt Holdings Limited Partners, James L L Tullis, Nmsic Co-Investment Fund, LP and Wendy S Johnson.
View institutional ownership trends
.

How do I buy shares of Exagen?

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exagen's stock price today?

One share of XGN stock can currently be purchased for approximately $2.89.

How much money does Exagen make?

Exagen (NASDAQ:XGN) has a market capitalization of $46.99 million and generates $48.30 million in revenue each year. The company earns $-26,850,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis.

How many employees does Exagen have?

The company employs 219 workers across the globe.

How can I contact Exagen?

Exagen's mailing address is 1261 Liberty Way Suite C, VISTA CA, 92081. The official website for the company is www.exagen.com. The company can be reached via phone at 760-560-1501 or via email at ir@exagen.com.

This page (NASDAQ:XGN) was last updated on 11/29/2022 by MarketBeat.com Staff